Last reviewed · How we verify
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma
Glaucoma, a progressive optic disc neuropathy causing visual field reduction, is the second leading cause of world blindness. The treatment of glaucoma is mainly based in reducing intraocular pressure (IOP) with topical medications. Many patients required two or more medications to achieve a target IOP. Combinations of B-blockers and prostaglandin analogs (PGA) are frequently used in clinical practice because their additive effect in lowering IOP levels. The aim of this study was to investigate the effects of fixed combinations of timolol maleate and PGA on the blood-aqueous barrier and evaluate the measurement of foveal thickness in pseudophakic patients with primary open-angle glaucoma (POAG).
Details
| Lead sponsor | University of Campinas, Brazil |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 69 |
| Start date | 2011-10 |
| Completion | 2013-01 |
Conditions
- Uveitis, Anterior
- Cystoid Macular Edema
Interventions
- travoprost and timolol maleate fixed combination
- latanoprost and maleate timolol fixed combination
- bimatoprost and timolol maleate fixed combination
- dextran and hypromellose
Primary outcomes
- Change of mean flare values from baseline at 6 months — Flare measurements occurred at baseline; after 15 days; and after 1, 2, 3, 4, 5, and 6 months of treatment
A flare measure of a laser flare meter (FM 500; Kowa Co Ltd, Tokyo, Japan) was used to determine the status of the blood-aqueous barrier at all follow-up visits. According to information provided by the manufacturer, flare readings greater than 26 photon counts per millisecond (p/ms) are indicative of a disruption in the blood-aqueous barrier.
Countries
Brazil